Consolidated September 2026 quarter: revenue up 41%; owners' profit after tax Rs 394.97 lakh
MAKERSL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.8 pts more than Nifty Microcap 250 and 8.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended 30 September 2026, revenue from operations was Rs 4,821.01 lakh, up 41.1% from Rs 3,417.45 lakh in the same quarter a year earlier; profit attributable to owners was Rs 394.97 lakh versus a loss of Rs 11.65 lakh. EBITDA margin rose to 25.1% from 6.9%. Consolidated half-year: revenue Rs 9,098.17 lakh, owners' profit Rs 545.40 lakh. Standalone quarter: revenue Rs 1,392.25 lakh, profit Rs 65.68 lakh.
Positive: strong revenue and margin growth, a return to profit and higher half-year earnings may support the stock.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.